Xoft

Xoft is a cutting-edge medical technology startup founded in 1998 and based in the United States. The company has developed the Xoft® Electronic Brachytherapy System®, which has received FDA clearance for treating various types of cancer, such as non-melanoma skin cancer, brain tumors, early stage breast cancer, and gynecological cancers. This innovative system uses a proprietary miniaturized x-ray as the radiation source, delivering precise treatment directly to cancerous areas while minimizing damage to healthy tissue and organs. The Xoft System has the advantage of being isotope-free, enabling it to be used in a wider range of clinical settings. It can be administered as a single course of radiation therapy during surgery through intraoperative radiation therapy (IORT) or in the form of partial breast irradiation (APBI). One distinguishing feature of the Xoft System is its mobility and small size, meaning it does not require a shielded environment and can be utilized in virtually any clinical setting. The latest recorded investment in Xoft stands at $968.06K, received in the form of debt financing on 12 July 2010. The company is currently undergoing a post-market study to evaluate the safety and efficacy of IORT with the Xoft System. For more information, interested parties can visit www.xoftinc.com. Overall, Xoft presents a compelling offering in the field of cancer treatment, leveraging innovative technology to provide more precise and adaptable radiation therapy solutions, sparking interest from potential venture capital candidates seeking disruptive advancements in the healthcare industry.